Versameb is funded by private international investors and aims to create substantial long term value
In its constant effort to bring new, differentiated mRNA therapies to patients rapidly, Versameb is backed by a group of private investors with both scientific and financial backgrounds.
Versameb is an active and decisive member of the Swiss biotech community, has excellent networks and collaborates with numerous renowned and respected institutions and corporations internationally.
Our goal is to create substantial long-term value for patients, shareholders and other stakeholders.
To find out more about investment opportunities with Versameb, please contact us.